
Sermorelin
Also called GHRH(1-29), GRF 1-29
- Evidence
- Limited research
- Class
- GHRH analog (secretagogue)
Sermorelin belongs to the GHRH analog (secretagogue) class. This library groups it under bones & muscles. Its source category is Not FDA-approved.
At a glance
| Compound class | GHRH analog (secretagogue) |
|---|---|
| Associated brands | (Geref - discontinued) |
| Body system | Bones & muscles |
| Use or research focus | Anti-aging, body composition, GH support |
| Regulatory status | Not FDA-approved as drug (Geref discontinued); available via compounding |
| Source evidence rating | Limited research |
How does Sermorelin work?
Stimulates pituitary GH release.
The source catalog maps this mechanism to Pituitary, Muscle, Adipose / Fat. A biological mechanism describes how a compound interacts with the body; it does not by itself prove a clinical benefit.
What does the evidence tell us?
The source catalog rates the evidence as limited. Laboratory and animal findings cannot establish benefits or safety in people. Small or early studies may raise useful research questions without supporting routine clinical use.
Use the Citations tab to examine the underlying sources. Look for human studies, a relevant comparison group, meaningful outcomes, and adequate follow-up. An ingredient, approved drug, and compounded preparation may have different evidence.
Safety and considerations
For an unapproved use or compound, safety and effectiveness may be uncertain. Products sold for research are not a substitute for prescribed care. Do not infer a human dose, injection protocol, or treatment recommendation from preclinical research.
This library is educational and does not provide dosing or treatment instructions. A listing here does not indicate that Peppy offers the compound.
Common questions
What is Sermorelin?
Sermorelin belongs to the GHRH analog (secretagogue) class. This library groups it under bones & muscles. Its source category is Not FDA-approved. Its recorded use or research focus is: Anti-aging, body composition, GH support.
Is Sermorelin FDA-approved?
The catalog records: Not FDA-approved as drug (Geref discontinued); available via compounding. Check the current product-specific regulatory information in the source links; a source category does not establish approval for every use or formulation.
How strong is the research?
The source catalog rates the evidence as limited. Laboratory and animal findings cannot establish benefits or safety in people. Small or early studies may raise useful research questions without supporting routine clinical use.
Where can I read the research?
The Citations tab contains 15 reference links from the source dataset. The original research guide provides additional context. These links are a starting point for reading the evidence.
More for bones & muscles
Factual catalog fields and citation links are adapted from Superpower’s Sermorelin guide and the public dataset linked in the reference post. Peppy’s explanations are educational; this page does not represent an independent clinical review of every linked study.
Sources & further reading
References associated with Sermorelin in the source dataset. Open a source to review its study design, population, limitations, and date.
- 01heredoi.org
- 02via somatostatin when levels are sufficientpubmed.ncbi.nlm.nih.gov
- 03cut visceral adipose tissue 15.2% at 26 weekspubmed.ncbi.nlm.nih.gov
- 04pooled analysis of two phase 3 trialspubmed.ncbi.nlm.nih.gov
- 05net 19% VAT reduction versus placebopubmed.ncbi.nlm.nih.gov
- 06GH response to a GHRH test was bluntedpubmed.ncbi.nlm.nih.gov
- 07IGF-1 rose from 159.5 to 239.0 ng/mLpubmed.ncbi.nlm.nih.gov
- 08increased slow-wave sleep from 14.0% to 20.2%pubmed.ncbi.nlm.nih.gov
- 09an almost 10-fold increase in slow-wave sleeppubmed.ncbi.nlm.nih.gov
- 10reduced nocturnal awakeningspubmed.ncbi.nlm.nih.gov
- 11for reasons of safety or effectivenessfederalregister.gov
- 12truncal muscle density increased by 1.56-4.86 Hounsfield unitspubmed.ncbi.nlm.nih.gov
- 13meta-analysis of five RCTspubmed.ncbi.nlm.nih.gov
- 14beginning in early adult lifepubmed.ncbi.nlm.nih.gov
- 15reduced hypothalamic GHRH output in older menpubmed.ncbi.nlm.nih.gov





